Astellas Gene Therapies: Overview

Astellas Gene Therapies (Astellas Gene), a subsidiary of Astellas Pharma Inc, is a biotechnology company that focuses on the development and commercialization of gene therapy products for rare diseases. The company’s major pipeline products include AT132, AT845, ASP2016, AT466 and KT430. It's products are used for the treatment of X-linked myotubular myopathy, pompe disease, muscular dystrophy in children and neuromuscular disease, severe respiratory insufficiency, weakness and hypotonia. The company explores three gene therapy modalities such as gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. Astellas Gene is headquartered in San Francisco, California, the US.